vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and TEAM INC (TISI). Click either name above to swap in a different company.

TEAM INC is the larger business by last-quarter revenue ($224.8M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 5.4%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 6.1%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

TeamViewer SE is an international technology company headquartered in Göppingen, Germany. The company became known for the TeamViewer remote access and support software of the same name. Within the TeamViewer software, customers can connect, monitor, and control computers, machines, and other devices. It can be used in various industries, for example, to digitalize processes along the industrial value chain. The company is listed on the stock exchange and is a member of MDAX and TecDAX.

ESPR vs TISI — Head-to-Head

Bigger by revenue
TISI
TISI
1.3× larger
TISI
$224.8M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+138.3% gap
ESPR
143.7%
5.4%
TISI
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
6.1%
TISI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
TISI
TISI
Revenue
$168.4M
$224.8M
Net Profit
$-3.8M
Gross Margin
25.9%
Operating Margin
50.6%
2.9%
Net Margin
-1.7%
Revenue YoY
143.7%
5.4%
Net Profit YoY
47.4%
EPS (diluted)
$0.32
$-1.46

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
TISI
TISI
Q4 25
$168.4M
$224.8M
Q3 25
$87.3M
$225.0M
Q2 25
$82.4M
$248.0M
Q1 25
$65.0M
$198.7M
Q4 24
$69.1M
$213.3M
Q3 24
$51.6M
$210.8M
Q2 24
$73.8M
$228.6M
Q1 24
$137.7M
$199.6M
Net Profit
ESPR
ESPR
TISI
TISI
Q4 25
$-3.8M
Q3 25
$-31.3M
$-11.4M
Q2 25
$-12.7M
$-4.3M
Q1 25
$-40.5M
$-29.7M
Q4 24
$-7.2M
Q3 24
$-29.5M
$-11.1M
Q2 24
$-61.9M
$-2.8M
Q1 24
$61.0M
$-17.2M
Gross Margin
ESPR
ESPR
TISI
TISI
Q4 25
25.9%
Q3 25
25.8%
Q2 25
27.5%
Q1 25
23.8%
Q4 24
26.9%
Q3 24
25.4%
Q2 24
27.8%
Q1 24
24.4%
Operating Margin
ESPR
ESPR
TISI
TISI
Q4 25
50.6%
2.9%
Q3 25
-11.4%
0.6%
Q2 25
8.6%
4.9%
Q1 25
-34.0%
-3.0%
Q4 24
-6.4%
1.0%
Q3 24
-31.0%
1.5%
Q2 24
3.5%
4.9%
Q1 24
52.5%
-3.2%
Net Margin
ESPR
ESPR
TISI
TISI
Q4 25
-1.7%
Q3 25
-35.9%
-5.1%
Q2 25
-15.4%
-1.7%
Q1 25
-62.2%
-15.0%
Q4 24
-3.4%
Q3 24
-57.2%
-5.3%
Q2 24
-83.9%
-1.2%
Q1 24
44.3%
-8.6%
EPS (diluted)
ESPR
ESPR
TISI
TISI
Q4 25
$0.32
$-1.46
Q3 25
$-0.16
$-2.68
Q2 25
$-0.06
$-0.95
Q1 25
$-0.21
$-6.61
Q4 24
$-0.14
$-1.60
Q3 24
$-0.15
$-2.52
Q2 24
$-0.33
$-0.63
Q1 24
$0.34
$-3.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
TISI
TISI
Cash + ST InvestmentsLiquidity on hand
$167.9M
$18.1M
Total DebtLower is stronger
$293.3M
Stockholders' EquityBook value
$-302.0M
$-24.5M
Total Assets
$465.9M
$485.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
TISI
TISI
Q4 25
$167.9M
$18.1M
Q3 25
$92.4M
$14.8M
Q2 25
$86.1M
$20.7M
Q1 25
$114.6M
$16.8M
Q4 24
$144.8M
$35.5M
Q3 24
$144.7M
$19.1M
Q2 24
$189.3M
$22.5M
Q1 24
$226.6M
$24.2M
Total Debt
ESPR
ESPR
TISI
TISI
Q4 25
$293.3M
Q3 25
$298.8M
Q2 25
$366.4M
Q1 25
$349.8M
Q4 24
$318.6M
Q3 24
$314.2M
Q2 24
$313.0M
Q1 24
$300.0M
Stockholders' Equity
ESPR
ESPR
TISI
TISI
Q4 25
$-302.0M
$-24.5M
Q3 25
$-451.4M
$-17.7M
Q2 25
$-433.5M
$-22.9M
Q1 25
$-426.2M
$-26.0M
Q4 24
$-388.7M
$1.7M
Q3 24
$-370.2M
$17.9M
Q2 24
$-344.2M
$23.9M
Q1 24
$-294.3M
$26.3M
Total Assets
ESPR
ESPR
TISI
TISI
Q4 25
$465.9M
$485.5M
Q3 25
$364.0M
$531.0M
Q2 25
$347.1M
$548.4M
Q1 25
$324.0M
$515.2M
Q4 24
$343.8M
$528.4M
Q3 24
$314.1M
$545.4M
Q2 24
$352.3M
$549.6M
Q1 24
$373.1M
$535.5M
Debt / Equity
ESPR
ESPR
TISI
TISI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
183.33×
Q3 24
17.55×
Q2 24
13.11×
Q1 24
11.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
TISI
TISI
Operating Cash FlowLast quarter
$45.2M
$16.8M
Free Cash FlowOCF − Capex
$14.6M
FCF MarginFCF / Revenue
6.5%
Capex IntensityCapex / Revenue
0.0%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-20.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
TISI
TISI
Q4 25
$45.2M
$16.8M
Q3 25
$-4.3M
$3.9M
Q2 25
$-31.4M
$-3.3M
Q1 25
$-22.6M
$-28.7M
Q4 24
$-35.0M
$21.6M
Q3 24
$-35.3M
$5.6M
Q2 24
$-7.2M
$-6.4M
Q1 24
$53.8M
$1.9M
Free Cash Flow
ESPR
ESPR
TISI
TISI
Q4 25
$14.6M
Q3 25
$1.0M
Q2 25
$-6.3M
Q1 25
$-30.1M
Q4 24
$19.6M
Q3 24
$-35.5M
$3.9M
Q2 24
$-7.3M
$-9.1M
Q1 24
$53.8M
$-1.1M
FCF Margin
ESPR
ESPR
TISI
TISI
Q4 25
6.5%
Q3 25
0.5%
Q2 25
-2.5%
Q1 25
-15.1%
Q4 24
9.2%
Q3 24
-68.7%
1.9%
Q2 24
-9.9%
-4.0%
Q1 24
39.0%
-0.6%
Capex Intensity
ESPR
ESPR
TISI
TISI
Q4 25
0.0%
0.9%
Q3 25
0.0%
1.3%
Q2 25
0.0%
1.2%
Q1 25
0.0%
0.7%
Q4 24
0.0%
0.9%
Q3 24
0.3%
0.8%
Q2 24
0.1%
1.2%
Q1 24
0.1%
1.5%
Cash Conversion
ESPR
ESPR
TISI
TISI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

TISI
TISI

Repairand Maintenance Services$114.8M51%
Non Destructive Evaluation And Testing Services$84.9M38%
Heat Treating$14.2M6%
Other Services$9.3M4%

Related Comparisons